Form 8-K - Current report:
SEC Accession No. 0001193125-24-200660
Filing Date
2024-08-14
Accepted
2024-08-14 16:30:57
Documents
15
Period of Report
2024-08-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d867868d8k.htm   iXBRL 8-K 28022
2 EX-10.1 d867868dex101.htm EX-10.1 743465
6 GRAPHIC g867868g0813084617349.jpg GRAPHIC 1679
  Complete submission text file 0001193125-24-200660.txt   1067432

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA biib-20240812.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE biib-20240812_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE biib-20240812_pre.xml EX-101.PRE 10818
17 EXTRACTED XBRL INSTANCE DOCUMENT d867868d8k_htm.xml XML 3477
Mailing Address 225 BINNEY STREET CAMBRIDGE MA 02142
Business Address 225 BINNEY STREET CAMBRIDGE MA 02142 7814642000
BIOGEN INC. (Filer) CIK: 0000875045 (see all company filings)

EIN.: 330112644 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19311 | Film No.: 241208624
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)